A

Actinium Pharmaceuticals

ATNM

6.63000
USD
-0.3
(-4.33%)
مغلق
حجم التداول
6,686
الربح لكل سهم
0
العائد الربحي
0
P/E
-1
حجم السوق
58,258,683
أصول ذات صلة
C
CAPR
-0.17000
(-4.19%)
3.89000 USD
C
CLDX
-0.540
(-1.42%)
37.560 USD
C
CRMD
-0.10000
(-2.19%)
4.47000 USD
C
CTIC
0.11000
(2.54%)
4.44000 USD
C
CYCC
0.02000
(1.22%)
1.66000 USD
M
MNKD
-0.21500
(-3.73%)
5.55000 USD
P
PIRS
0.480
(2.91%)
16.990 USD
T
TNXP
0.00960
(1.92%)
0.51050 USD
الأخبار المقالات

العنوان: Actinium Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.